Alzheimer’s drug from Eisai and Biogen gets FDA accelerated approval
Trials showed €25,000 a year drug slowed rate of cognitive decline in patients with early Alzheimer’s by 27% compared to a placebo.
Trials showed €25,000 a year drug slowed rate of cognitive decline in patients with early Alzheimer’s by 27% compared to a placebo.
Future of Aduhelm was in doubt after Medicare restricted coverage to clinical trials
Many scientists opposed approval of controversial treatment, saying it did not work
Investors hope a gridlock in US congress would be able to stall major policy changes
Dublin market closed marginally higher with food stocks leading the way
Pharma group resurrects pipeline therapy it abandoned as ineffective earlier this year
Iseq overall index again underperformed European peers, up 0.12 per cent
Market report: Iseq overall index again underperformed European peers, up 0.12 per cents
Japan’s main index ends the week 2.4% higher after rally
The cost of powerful new drugs is pushing health budgets to the limit
Crosswords & puzzles to keep you challenged and entertained
Inquests into the nightclub fire that led to the deaths of 48 people
How does a post-Brexit world shape the identity and relationship of these islands
Weddings, Births, Deaths and other family notices